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clinically and genetically heterogeneous. Genetic causes include
defects of mitochondrial aminoacyl-tRNA synthetases, and fac-
tors required for initiation, elongation and termination of pro-
tein synthesis as well as ribosome recycling. We report on a new
case of myopathy, lactic acidosis and sideroblastic anemia
(MLASA) syndrome caused by defective mitochondrial tyrosyl
aminoacylation. The patient presented at 1 year with anemia
initially attributed to iron deficiency. Bone marrow aspirate at
5 years revealed ringed sideroblasts but transfusion dependency
did not occur until 11 years. Other clinical features included
lactic acidosis, poor weight gain, hypertrophic cardiomyopathy
and severe myopathy leading to respiratory failure necessitating
ventilatory support. Long-range PCR excluded mitochondrial
DNA rearrangements. Clinical diagnosis of MLASA prompted
direct sequence analysis of the YARS2 gene encoding the mito-
chondrial tyrosyl-tRNA synthetase, which revealed homozygos-
ity for a known pathogenic mutation, c.156C>G;p.F52L.
Comparison with four previously reported cases demonstrated
remarkable clinical homogeneity. First line investigation of
MLASA should include direct sequence analysis of YARS2 and
PUS1 (encoding a tRNAmodification factor) rather thanmuscle
biopsy. Early genetic diagnosis is essential for counseling and to
facilitate appropriate supportive therapy. Reasons for segrega-
tion of specific clinical phenotypes with particular mitochondri-
al aminoacyl tRNA-synthetase defects remain unknown.
 2013 The Authors. American Journal of Medical Genetics Part A/ Published
by Wiley Periodicals, Inc.
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The congenital sideroblastic anemias are rare inborn errors of
metabolism caused by defects of mitochondrial energy production,2013 The Authors. American Journal of Medical Genetics Parheme biosynthesis and iron–sulfur cluster biogenesis [Bergmann
et al., 2010; Fleming, 2011]. The most commonly recognized
congenital sideroblastic anemias are X-linked sideroblastic anemia
(XLSA) secondary to mutations in ALAS2 encoding delta amino
levulinic acid synthetase, and the Pearson marrow-pancreas syn-
drome caused by sporadically arising large-scale rearrangements of
the mitochondrial genome. Mitochondrial DNA (mtDNA) enc-
odes 13 polypeptide subunits of the oxidative phosphorylationt A/ Published by Wiley Periodicals, Inc. 2334
SHAHNI ET AL. 2335(OXPHOS) system, together with 22 transfer RNA (tRNA) and two
ribosomalRNA(rRNA)molecules required for intramitochondrial
synthesis of these 13 polypeptides. The mtDNA rearrangements in
Pearson syndrome typically delete several tRNA genes, leading to
global impairment ofmitochondrial translation [Rotig et al., 1995].
More recently, nuclear-encoded disorders of mitochondrial trans-
lation are emerging including two gene defects (PUS1 and YARS2
mutations) that appear to specifically associate with a syndrome of
myopathy, lactic acidosis and sideroblastic anemia (MLASA)
[Bykhovskaya et al., 2004; Riley et al., 2010; Rotig, 2011].
XLSA and Pearson syndrome can be easily distinguished clini-
cally since the former causes a pure sideroblastic anemia phenotype
(which may be late-onset and not require regular transfusions),
whilst the latter causes an infantile-onset transfusion-dependent
sideroblastic anemia associated with lactic acidosis and multisys-
tem disturbances. Clinical manifestations of Pearson syndrome
include exocrine and endocrine pancreatic insufficiency, renal
tubulopathy and faltering growth [Rotig et al., 1995]. Death in
infancy or early childhood frequently follows overwhelming lactic
acidosis or acute liver failure [Rotig et al., 1995]. Survivorsdevelopa
progressive neurological disorder including ophthalmoplegia, car-
diac conduction defects and cerebellar ataxia, within the Kearns–
Sayre syndrome spectrum [McShane et al., 1991; Rahman and
Leonard, 2000].
YARS2mutations have previously been reported in four patients
from three apparently unrelated families [Riley et al., 2010; Sasar-
man et al., 2012]. Here we describe another case of MLASA caused
by YARS2 mutation and show that this is a clinically distinct
phenotype that can be diagnosed without recourse to muscle
biopsy, the “gold-standard” method for diagnosing mitochondrial
disease.PATIENT AND METHODS
Thepatient, the second child of healthy unrelated Lebanese parents,
was born at term after an uncomplicated pregnancy. Two siblings
aged 7 and 16 years are healthy. Aged 1 year, following an episode of
pallor and jaundice, the patient was diagnosed with iron deficiency
anemia and was prescribed iron supplements. At 5 years, the family
migrated to the UK and he was diagnosed with congenital side-
roblastic anemia following a bone marrow aspirate (Fig. 1a).
Pyridoxine was commenced and his hemoglobin remained stable
(9–11 g/dl) until 11.5 years. At 10 years he presented with abdomi-
nal pain, poorweight gain and lethargy.Upper gastrointestinal (GI)
endoscopy revealed reflux esophagitis and patchy duodenal ery-
thema with mild focal lymphocyte infiltration. Poor growth and
intermittent vomiting persisted despite serial interventions includ-
ing gluten-free diet and nasogastric, gastrostomy and (eventually)
parenteral feeding. Repeat upper GI endoscopy and video capsule
endoscopy revealedmultiple ileal ulcers, and an atrophic duodenal
bulb, with absent villi and duodenal ulcers. A trial of azathioprine
and prednisolone was commenced for presumed inflammatory
bowel disease.
At 11.5 years he developed transfusion-dependent anemia;
repeat bone marrow aspiration and trephine biopsy appearances
were unchanged. The worsening anemia was initially attributed to
chronic low-grade gastrointestinal bleeding. He also requiredtwice-weekly granulocyte colony stimulating factor infusions for
neutropenia. Nine months later he developed shortness of breath
and was found to have a pericardial effusion, necessitating peri-
cardiocentesis. Transthoracic echocardiogram also showed severe
biventricular hypertrophy with preserved biventricular systolic
function. Due to recurrent episodes of dizziness he underwent
24 hr Holter monitoring which showed sinus rhythm.
At 12.5 years he became increasingly lethargic, with declining
weight despite parenteral nutrition and regular transfusions every
2–3 weeks. Examination showed myopathic facies, bilateral ptosis,
pallor and cachexia, (weight 23.6 kg, 0.4th centile and height
139.9 cm, 2nd centile), with generalized muscle weakness. Electro-
myography demonstrated severe myopathic changes. Sleep study
revealed severe hypoventilationwith evidence of CO2 retention and
he was commenced on nocturnal BiPAP ventilation. Blood inves-
tigations showed anemia (Hb 6.28.4 g/dl), neutropenia (neutro-
phils 0.26  109/L), elevated lactate and respiratory acidosis
(venous blood gas pH 7.3, pCO2 9.9 kPa, HCO3 37 mmol/L).
Plasma amino acids demonstrated raised alanine (1113 mmol/L,
reference range 150–450) and low arginine (28 mmol/L, reference
range 40–120). Acylcarnitine analysis revealed low free carnitine
levels. Urine organic acid analysis demonstrated strongly raised
lactate andpyruvatewithmoderately raised 2-hydroxybutyrate and
mildly raised 2-hydroxyisovalerate, secondary to disturbed lactate
metabolism. Stool elastase was normal (>500 mg/g, normal>200).
All genetic studies were performed with informed parental
consent and ethical approval for the study was obtained from
the National Research Ethics Committee London Bloomsbury,
UK. Long-range PCR of mitochondrial DNA was used to screen
for large-scale mtDNA rearrangements. Because of a clinical suspi-
cion of MLASA syndrome, and the Lebanese origin of the patient,
theYARS2 genewas sequenced in the patient andbothparents. PCR
amplification was performed using primers and conditions as
previously reported, and PCR products were directly sequenced
on an ABI PRISM 3730 automated sequencer (Source Biosciences)
[Riley et al., 2010]. Sequence comparisons and analysis were
performed using the Sequencher program, V.4.9.RESULTS
Long range PCR of genomic DNA extracted from peripheral blood
leucocytes did not detect any mtDNA rearrangements, excluding
Pearson syndrome. On the basis of phenotype similarities between
our patient and previously reported patients we sequenced the
YARS2 gene, which encodes the human mitochondrial tyrosyl-
RNA synthetase, and identified a homozygous mutation, c.156C
> G;p.F52L (Fig. 1b), which affects a highly conserved amino acid
residue and has previously been reported to be pathogenic [Riley
et al., 2010].DISCUSSION
The combination of sideroblastic anemia and lactic acidosis is
strongly suspicious of a mitochondrial disorder. In infantile-onset
sideroblastic anemia with lactic acidosis, the most frequent cause is
Pearson marrow-pancreas syndrome associated with single large-
scale mtDNA rearrangements. Several lines of evidence argued
FIG. 1. a: Bone marrow aspirate stained for iron with Perls’ Prussian blue stain (original magnification 60). Arrows indicate two of the
numerous ringed sideroblasts seen. b: Sequence electropherogram of part of exon 1 of the YARS2 gene. The control sequence is wild-type
homozygous (top panel) whilst the patient is homozygous for the c.156C>G mutation resulting in proline to leucine substitution (second
panel) and the parents are both heterozygous (lower two panels).
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dependency at 13 years (in Pearson syndrome transfusion depen-
dency typically resolves by the age of 2 years, as mutant mtDNA is
progressively cleared from rapidly dividing hemopoietic cells),
absence of pancreatic insufficiency (normal stool elastase levels),
lack of neurological symptoms other than myopathy by teenage
years (inparticular, no evidenceof cerebellar ataxia), and absence of
renal tubulopathy, pigmentary retinopathy and sensorineural hear-
ing loss (which are all typical of Pearson and Kearns–Sayre syn-
dromes) [Pitceathly et al., 2012]. The bone marrow appearances
were also atypical for Pearson syndrome, in which there is usually
vacuolization of early erythroid and myeloid progenitors in addi-
tion to thepresence of ringed sideroblasts,whereas inourpatient no
significant vacuolization was seen. Finally, Pearson syndrome was
definitively excluded in our patient by the absence of mtDNA
rearrangements in leukocyte DNA.
A clinically more fitting diagnosis in our patient was MLASA,
that is, mitochondrial myopathy, lactic acidosis and sideroblastic
anemia syndrome. This was confirmed by YARS2 analysis, which
revealed homozygosity for the known pathogenic mutation c.156C
>G;p.F52L. Parents were both heterozygous for the mutation,
although they are not known to be related, lending weight to the
hypothesis that this is a Lebanese founder mutation [Riley
et al., 2010]. Two different homozygous mutations have been
reported in YARS2, c.156C>G;p.F52L (as in our patient) and
c.137G>A;p.G46D, in three apparently unrelated families of Leb-
anese descent. Our patient is the fifth with YARS2 mutations
reported to date. All five patients had MLASA.A characteristic clinical phenotype of YARS2-related MLASA
syndrome appears to be emerging (Table I). Gastro-intestinal
disturbance and feeding difficulties appear to occur frequently in
MLASA, whereas exocrine pancreatic insufficiency (a cardinal
feature of Pearson syndrome) has never been reported. Respiratory
failure requiring ventilatory support and cardiomyopathy were
present in two cases including ours. In Pearson and Kearns–Sayre
syndromes cardiomyopathy may occur, but the most significant
cardiac problem is usually heart block, which has not been reported
in MLASA. Compared to Pearson syndrome, hearing and vision
appear to be relatively spared in YARS2-associated MLASA. One
case had asymmetric ptosis and limitation of lateral gaze bilaterally
in his thirties [Sasarman et al., 2002], while no hearing loss was
reported in any of the five cases.
There appears to be a common pathogenic mechanism in
Pearson syndrome and MLASA, namely global impairment of
mitochondrial translation, manifest histologically by a ragged-
red fiber myopathy with subsarcolemmal mitochondrial prolifera-
tion. In Pearson syndromemultiple mitochondrial tRNA genes are
deleted, whilst in MLASA caused by PUS1 mutations there is a
defect in post-transcriptional modification (pseudouridylation) of
multiple mitochondrial and cytosolic tRNAs [Patton et al., 2005].
YARS2 mutations lead to failure of aminoacylation of the mito-
chondrial tRNA tyrosine. Interestingly the common 4,977 bp
mtDNA deletion causing Pearson syndrome does not include
the tRNA for tyrosine [Rotig et al., 1995]. Only two mutations
have previously been reported in the MT-TY gene encoding the
mitochondrial tRNA tyrosine molecule, and neither of these was
TABLE I. Clinical Phenotype Associated with YARS2 Autations
Reference Riley et al. [2010] Sasarman et al. [2012] a This report
Patient P1 P2 P3 P4 P5
Sex M F F M M
Age at onset 10 weeks Infancy 7y 31y 1y
Age at death 18y Alive at 16y Alive at 24y Alive at 34y Alive at 13y
Consanguinity Yes Yes Yes No
Family history Sibling (P2) Sibling (P1) Maternal aunt
died of SA
at 26yb
No Paternal uncle
similarly affectedb
Ethnicity Lebanese Lebanese Lebanese Lebanese Lebanese
Sideroblastic anemia Yes Yes Yes Yes Yes
Transfusion-dependent Yes—initially
2–3 monthly,
later every
3–4 weeks
Yes No No From 11.5y
Faltering growth Yes — — — Yes
Dysphagia/feeding
difficulties
Yes—eventually
permanent
vocal cord
paresis
Yes — — Yes
Hypertrophic
cardiomyopathy
Yes — — — Yes
Exercise intolerance Yes Yes Yes Yes Yes
Respiratory failure 17y — No — 12y
Blood lactate (mmol/L) 3–13.7 2.5–8.4 4.1 3.8 5.6–10.1
Muscle histology “Incipient , reduced
COX staining
Lipid vacuoles Severely reduced
COX staining and
increased SDH;
EMsubsarcolemmal
aggregation of
peripheral mitochondria,
many containing
crystalline inclusions
ND
Muscle respiratory
chain enzyme
activities
(% of control)
CI CI CI CI (<6%) ND
CIV CIII CIV CIII (41%)
CIV CIV (4%)
YARS2 mutations Homozygous Homozygous Homozygous Homozygous c.137G >
A;p.G46D
Homozygous
c.156C > G;p.52L c.156C > G;p.52L c.156C > G;p.52L c.156C > G;p.52L
Key: CI, complex I; CII þ III, complexes II þ III; CIII, complex III; CIV, complex IV; COX, cytochrome c oxidase; ND, not determined; RRF, ragged red fibres;—, information not provided in original report.aClinical
features of P4 initially reported in Sasarman et al. [2002].
bThese individuals have not been tested for YARS2 mutations.
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impaired translation of tyrosine residues is not the cause of side-
roblastic anemia [Pulkes et al., 2000; Scaglia et al., 2003]. However,
the twopatients didhave someclinical features in commonwithour
patient with YARS2 mutations, namely myopathy and lactic aci-
dosis in the first case and cardiomyopathy in the second, arguing for
a role for impaired tyrosine aminoacylation in causation of some of
the features ofMLASA [Pulkes et al., 2000; Scaglia et al., 2003]. The
mechanistic link between YARS2 and PUS1 mutations is alsounclear. PUS1 has been shown to modify bases 27 and/or 28 of
several mitochondrial tRNA species [Suzuki et al., 2011], but the
pseudouridylation status of mitochondrial tRNA tyrosine has not
yet been reported.
Defects of several other mitochondrial tRNA aminoacyl synthe-
tases do not appear to cause congenital sideroblastic anemia
[Konovalova and Tyynismaa, 2013]. Moreover, a large number
of nuclear-encoded mitochondrial translation defects have now
been described and most are not associated with congenital side-
2338 AMERICAN JOURNAL OF MEDICAL GENETICS PART Aroblastic anemia [Rotig, 2011]. The reasons for the tissue specificity
associated with YARS2 and PUS1 mutations are currently not
understood, but it is possible that the YARS2 protein has a second
function necessary for hematopoeisis that may be unrelated to its
role in mitochondrial protein synthesis. Moonlighting functions
are recognised for other mitochondrial proteins, for example one
subunit of respiratory chain complex I is a tumour suppressor and
another is involved in caspase-independent cell death, whilst vari-
ous complex I assembly factors have been implicated in immune
pathways and to enhance tumour growth in some cancers [Rahman
and Thorburn, 2013].
In conclusion, patients with congenital sideroblastic anemia
should be assessed for features ofMLASA and consideration should
be given to screening theYARS2 gene in patients with lactic acidosis
and sideroblastic anemia persisting beyond early childhood, par-
ticularly if mtDNA deletions have been excluded. Although no
specific curative therapies are available, early diagnosis and initia-
tion of appropriate supportive therapy is likely to be important in
the prevention of the longterm complications of this disorder.
Direct targeting of the YARS2 and PUS1 genes in MLASA patients
can avoid invasive muscle biopsy for diagnosis of this subgroup of
inborn errors of mitochondrial metabolism.
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